EGLN3

Across TCGA pan-cancer cohorts, EGLN3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EGLN3 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher EGLN3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EGLN3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, LUAD, and UCEC are the cancer types where EGLN3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
LUAD	OS	Median	III,IV	0.134	0.670	<.001	15	view →
UCEC	DFS	Median	All	1.000	0.629	.030	14	view →
CESC	DFS	Median	All	0.592	0.822	.015	12	view →
COAD	OS	Median	All	0.242	0.806	.024	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	III,IV	0.089	0.616	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EGLN3–STAD (OS)

Open the STAD breakdown →